These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice. Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609 [TBL] [Abstract][Full Text] [Related]
10. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F; Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862 [TBL] [Abstract][Full Text] [Related]
11. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. Scheffler A; Schenk H; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Holle D J Headache Pain; 2021 Sep; 22(1):111. PubMed ID: 34544359 [TBL] [Abstract][Full Text] [Related]
12. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795 [TBL] [Abstract][Full Text] [Related]
13. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696 [TBL] [Abstract][Full Text] [Related]
15. The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial. Sirilertmekasakul C; Panto A; Lekhalawan P; Panyarachun P; Jindasakchai P; Rattanawong W Neurol Sci; 2024 Apr; ():. PubMed ID: 38564060 [TBL] [Abstract][Full Text] [Related]